Martin David Harp

The EXTEND trial provided 5-year follow-up for 10 patients with advanced retinitis pigmentosa, who had previously received MCO-010 during a phase 1/2a trial

SPVN20 is a gene-agnostic, intravitreal AAV-based gene therapy that targets dormant cones to restore vision, according to SparingVision

Anat Loewenstein, MD, shared recent research findings which indicate home monitoring is appropriate for atypical and complex pathologies

María Berrocal, MD, spoke about the Vit-Buckle Society (VBS), which has become a regular feature at the European Society of Retina Specialists annual meeting

Prof Romano stressed the importance of matching procedure to patient, not just mastering technical vitrectomy skills

Today, over 150 practitioners from 20 countries in Australia, Asia and Europe enter their patient data into the Fight Retinal Blindness! Registry

At the EURETINA congress, Prof Boon discussed controversies in treatment, some driven by critical prospective studies

Alteogen received a positive CHMP opinion for EYLUXVI in July 2025

Prof Stanzel detailed new advancements in proliferative vitreoretinopathy and a hyperaspheric IOL designed for patients with age-related macular degeneration

Discover how the International Retinal Imaging Society fosters collaboration among specialists to advance retinal imaging and transform clinical practices.

The Vit-Buckle Symposium fosters global collaboration among eye care professionals, emphasizing interactive learning through challenging surgical case discussions.

The province's public health insurance scheme, Régie de l’assurance maladie du Québec (RAMQ), covers faricimab for three indications

A 12-month follow-up indicated no dose limiting toxicity and no ocular or systemic adverse effects

Sandoz will hold exclusive or semi-exclusive marketing rights in several European and Asian countries

João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases

The transaction is anticipated to close in 6 to 12 months subject to customary closing conditions and regulatory approval

According to the company, the EMA’s opinion was based on the “totality of evidence comprising a comprehensive analytical, non-clinical and clinical data package”

The nitric oxide-donating bimatoprost therapy is intended to lower intraocular pressure in patients with glaucoma or ocular hypertension

With fewer injections and sustained vision gains, the updated Eylea regimen offers new hope for patients with age-related macular degeneration and diabetic macular edema.

The study will be led by principal investigator professor Noemi Lois, MD, PhD, FRCS(Ed), FRCOphth, at Queen’s University Belfast, in over 20 clinical sites, and plans to enroll 264 patients across the UK with severe DME.

The Tecnis Odyssey, launched in the US in October 2024, is now available in Europe, the Middle East and Canada

Detecting mitochondrial dysfunction may give clinicians a chance to reduce the rate of cognitive decline in patients with dementia

At the 2025 ARVO annual meeting, Prof Sadun shared an exciting update in our understanding of Leber hereditary optic neuropathy

Prof Loewenstein and a cohort of colleagues assessed the current treatment outlook for patients with diabetic retinopathy

Carl Zeiss Meditec plans to launch the ZEISS RDP in select countries throughout 2025

The US Food and Drug Administration did not identify any safety or efficacy issues associated with aflibercept 8 mg

Bangalore-based Eyestem will share more research findings on Eyecyte-RPE at this year's Association for Research in Vision and Ophthalmology meeting

Ophthalmologists report that dry eye syndrome, myopia progression and other ocular pathologies have increased, especially among paediatric patient groups